The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Medical Progress
PreviousPrevious
Volume 350:482-492 January 29, 2004 Number 5
NextNext

Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring
Ernani Luis Rhoden, M.D., and Abraham Morgentaler, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Commentary
-Perspective
 by Snyder, P. J.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
Hypogonadism is a clinical condition in which low levels of serum testosterone are found in association with specific signs and symptoms, including diminished libido and sense of vitality, erectile dysfunction, reduced muscle mass and bone density, depression, and anemia (Table 1). When hypogonadism occurs in an older man, the condition is often called andropause, or androgen deficiency of the aging male.

View this table:
[in this window]
[in a new window]
 
Table 1. Hypogonadism.

 
Hypogonadism affects an estimated 2 million to 4 million men in the United States; its prevalence increases with age (Figure 1). 1,2 However, it has been estimated that only 5 percent of affected men currently . . . [Full Text of this Article]

Forms of Testosterone Available for Administration

Risks of Testosterone-Replacement Therapy

Testosterone Supplementation and Cardiovascular Risk

Coronary Artery Disease

Lipid Profiles

Polycythemia

Testosterone-Replacement Therapy and the Prostate

Benign Prostatic Hyperplasia

Prostate Cancer

PSA

Other Potential Adverse Effects

Hepatic Effects

Sleep Apnea

Miscellaneous Effects of Testosterone

Monitoring during Therapy


Source Information

From the Division of Urology, Beth Israel Deaconess Medical Center, and Harvard Medical School — both in Boston.

Address reprint requests to Dr. Morgentaler at 1 Brookline Pl., Suite 624, Brookline, MA 02445, or at amorgent@caregroup.harvard.edu.


Related Letters:

Risks of Testosterone Replacement
Shames D. A., Schaeffer E. M., Walsh P. C., Redmond G., Harris R. M., Morgentaler A., Rhoden E. L.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2004-2006, May 6, 2004. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.